vs

Side-by-side financial comparison of AVINO SILVER & GOLD MINES LTD (ASM) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $21.0M, roughly 1.3× AVINO SILVER & GOLD MINES LTD). AVINO SILVER & GOLD MINES LTD runs the higher net margin — 36.6% vs -71.0%, a 107.6% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 44.0%).

Avino Silver & Gold Mines Ltd is a Canada-based mining company engaged in the exploration, development, and production of precious and base metals, primarily silver, gold, and copper. It operates its flagship Avino Mine property in Durango, Mexico, with its metal products supplied to global industrial and commodity markets.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

ASM vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.3× larger
ZYME
$27.6M
$21.0M
ASM
Growing faster (revenue YoY)
ZYME
ZYME
+28.6% gap
ZYME
72.6%
44.0%
ASM
Higher net margin
ASM
ASM
107.6% more per $
ASM
36.6%
-71.0%
ZYME

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
ASM
ASM
ZYME
ZYME
Revenue
$21.0M
$27.6M
Net Profit
$7.7M
$-19.6M
Gross Margin
47.1%
Operating Margin
-80.1%
Net Margin
36.6%
-71.0%
Revenue YoY
44.0%
72.6%
Net Profit YoY
558.9%
34.3%
EPS (diluted)
$0.05
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASM
ASM
ZYME
ZYME
Q3 25
$21.0M
$27.6M
Q2 25
$21.8M
$48.7M
Q1 25
$18.8M
$27.1M
Q4 24
$31.0M
Q3 24
$14.6M
$16.0M
Q2 24
$14.8M
$19.2M
Q1 24
$12.4M
$10.0M
Q3 23
$12.3M
Net Profit
ASM
ASM
ZYME
ZYME
Q3 25
$7.7M
$-19.6M
Q2 25
$2.9M
$2.3M
Q1 25
$5.6M
$-22.6M
Q4 24
$-23.5M
Q3 24
$1.2M
$-29.9M
Q2 24
$1.2M
$-37.7M
Q1 24
$599.0K
$-31.7M
Q3 23
$-803.0K
Gross Margin
ASM
ASM
ZYME
ZYME
Q3 25
47.1%
Q2 25
46.9%
Q1 25
56.1%
Q4 24
Q3 24
39.1%
Q2 24
31.8%
Q1 24
18.9%
Q3 23
19.2%
Operating Margin
ASM
ASM
ZYME
ZYME
Q3 25
-80.1%
Q2 25
-1.4%
Q1 25
-94.5%
Q4 24
-71.6%
Q3 24
-213.8%
Q2 24
-222.9%
Q1 24
-376.9%
Q3 23
Net Margin
ASM
ASM
ZYME
ZYME
Q3 25
36.6%
-71.0%
Q2 25
13.1%
4.8%
Q1 25
29.8%
-83.5%
Q4 24
-75.8%
Q3 24
8.0%
-186.6%
Q2 24
8.4%
-195.8%
Q1 24
4.8%
-315.6%
Q3 23
-6.5%
EPS (diluted)
ASM
ASM
ZYME
ZYME
Q3 25
$0.05
$-0.26
Q2 25
$0.02
$0.03
Q1 25
$0.04
$-0.30
Q4 24
$-0.32
Q3 24
$0.01
$-0.39
Q2 24
$0.01
$-0.49
Q1 24
$0.00
$-0.42
Q3 23
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASM
ASM
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$57.3M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$182.1M
$320.1M
Total Assets
$221.9M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASM
ASM
ZYME
ZYME
Q3 25
$57.3M
$64.8M
Q2 25
$37.3M
$98.3M
Q1 25
$26.6M
$76.2M
Q4 24
$66.1M
Q3 24
$7.8M
$122.4M
Q2 24
$5.3M
$71.0M
Q1 24
$3.5M
$114.8M
Q3 23
$1.9M
Stockholders' Equity
ASM
ASM
ZYME
ZYME
Q3 25
$182.1M
$320.1M
Q2 25
$144.8M
$334.5M
Q1 25
$132.3M
$325.0M
Q4 24
$338.8M
Q3 24
$114.5M
$367.0M
Q2 24
$112.2M
$406.2M
Q1 24
$107.8M
$438.0M
Q3 23
$102.7M
Total Assets
ASM
ASM
ZYME
ZYME
Q3 25
$221.9M
$397.3M
Q2 25
$174.7M
$408.4M
Q1 25
$157.7M
$425.5M
Q4 24
$463.1M
Q3 24
$135.4M
$487.2M
Q2 24
$133.7M
$515.6M
Q1 24
$128.6M
$553.8M
Q3 23
$123.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASM
ASM
ZYME
ZYME
Operating Cash FlowLast quarter
$8.3M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
1.08×
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASM
ASM
ZYME
ZYME
Q3 25
$8.3M
$-31.4M
Q2 25
$8.3M
$12.1M
Q1 25
$758.0K
$-3.4M
Q4 24
$-41.5M
Q3 24
$4.1M
$-5.9M
Q2 24
$1.1M
$-25.0M
Q1 24
$2.3M
$-37.7M
Q3 23
$-83.0K
Free Cash Flow
ASM
ASM
ZYME
ZYME
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
Q3 23
FCF Margin
ASM
ASM
ZYME
ZYME
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Q3 23
Capex Intensity
ASM
ASM
ZYME
ZYME
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Q3 23
Cash Conversion
ASM
ASM
ZYME
ZYME
Q3 25
1.08×
Q2 25
2.92×
5.21×
Q1 25
0.13×
Q4 24
Q3 24
3.55×
Q2 24
0.87×
Q1 24
3.92×
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons